Trials / Unknown
UnknownNCT03690310
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
An Observational Clinical Study on the Safety and Efficacy of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Allife Medical Science and Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 CAR NK cells in patients with relapsed refractory B cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Anti-CD19 CAR NK Cells | Anti-CD19 CAR NK Cells injection |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2020-11-01
- Completion
- 2021-11-01
- First posted
- 2018-10-01
- Last updated
- 2019-01-31
Source: ClinicalTrials.gov record NCT03690310. Inclusion in this directory is not an endorsement.